The Role of Endothelial Dysfunction in Adult Polycystic Kidney Disease

Endothelial Dysfunction in Autosomal Dominant Polycystic Kidney Disease

This pilot study will compare endothelial function in patients with ADPKD with matched healthy volunteers and normotensive chronic kidney disease stage 1 & 2 patients. Patients will undergo a single assessment of endothelial function and measurement of plasma and urine levels of biomarkers of endothelial function.

Study Overview

• Status: Completed
• Conditions: Polycystic Kidney, Autosomal Dominant
• Intervention / Treatment: Diagnostic test: Peripheral (digital) arterial tonometry

Detailed Description

Following recruitment we will record the following baseline demographics; age, gender, smoking status, body mass index, medical history.

Participants will undergo a noninvasive vascular assessment, venepuncture and will provide a urine sample.This will be done during a single visit to the CRF.

Noninvasive vascular assessment will consist of:

1. Peripheral Arterial Tonometry This will be measured using the EndoPAT system (Itamar Medical)

   Endothelial shear stress flow stimulus will be provided by inflation of a blood pressure cuff around the upper non-dominant arm to suprasystolic pressure (but <300mmHg) for 5 minutes. Following release of the cuff the resulting digital microcirculation vasodilatory response to ischaemic hyperaemia, quantified as the pulse wave amplitude, will be monitored over 5 minutes. The peak pulse wave amplitude measured at 90-150s post cuff deflation relative to baseline will be indexed to the changes in the opposite arm to give the reactive hyperaemia index. This measure of endothelial function constitutes the outcome measure.

2. Blood Pressure Assessment Brachial artery blood pressure will be measured in the left arm in the supine position using an automated device (Dinamap) and in accordance with the clinical research facility SOP.
3. Blood samples and urine samples

Samples for plasma will be centrifuged and stored at -80C. Biochemical analysis will be performed by the laboratory of the STH NHS Trust for standard tests and by validated assays for non-routine markers (as detailed below) in the Academic Nephrology Unit.

Participants will be asked to collect a 24h urine sample from the day before the study visit and to provide a spot urine sample on the day. This will be analysed at the laboratory of the STH NHS Trust.

Biochemical Analysis

Serum samples will be analyzed for Full blood count, Urea, Electrolytes, Glucose, Insulin, Lipid Profile, Homocysteine, (Hs) CRP and Creatinine Levels.

Serum and plasma will also be stored for future analysis of relevant biomarkers of endothelial function or nitric oxide metabolism as indicated by preliminary results.

Urine samples will be analysed initially for protein creatinine ratio (PCR). The rest will be frozen for future analysis of urinary biomarkers of endothelial function or nitric oxide metabolism.

• Study Type: Observational
• Enrollment (Actual): 40

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 50 years (Adult)
• Accepts Healthy Volunteers: Yes
• Genders Eligible for Study: All

• Sampling Method: Non-Probability Sample

Study Population

Normotensive ADPKD patients with well preserved GFR (>60ml/min) ie those with Stage 1 or 2 Chronic Kidney Disease recruited from a specialist PKD clinic. Healthy controls will be recruited matched to age, sex, body mass index (BMI) and eGFR of the ADPKD patients.

Description

Inclusion Criteria:

• Age >18yrs, <50yrs
• Able to understand spoken/written English sufficiently to give informed consent and to take part in clinical assessment
• Clinical diagnosis of ADPKD
• eGFR >60ml/min/1.73m2

Exclusion Criteria:

• No history of cardiovascular disease or hypertension
• Not diabetic
• Not smoking
• Not breastfeeding
• Not pregnant
• Not taking any regular medication (except oral contraceptives)
• No musculoskeletal conditions contraindicating inflation of a blood pressure cuff to suprasystolic pressures around the forearm (as part of EndoPAT measurements)
• Not morbidly obese: BMI<35 (May contribute to endothelial dysfunction)
• eGFR <60ml/min/1.73m2

Study Plan

How is the study designed?

Number of groups / cohorts

2

Cohorts and Interventions

Group / Cohort	Intervention / Treatment
Controls; Healthy volunteers	Diagnostic test: Peripheral (digital) arterial tonometry; This will be measured using the EndoPAT system (Itamar Medical)
ADPKD; ADPKD patients	Diagnostic test: Peripheral (digital) arterial tonometry; This will be measured using the EndoPAT system (Itamar Medical)

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Reactive hyperemia index (RHI)	EndoPAT values (Endoscore)	Baseline

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Systolic and diastolic Blood pressure	mm Hg	Baseline
Proteinuria	Protein creatinine ratio	Baseline

Collaborators and Investigators

• Sponsor: Sheffield Teaching Hospitals NHS Foundation Trust
• Collaborators: University of Sheffield
• Investigators: Principal Investigator: Albert Ong, STH; Study Director: Timothy Chico, STH

Study record dates

Study Major Dates

• Study Start (Actual): July 25, 2011
• Primary Completion (Actual): December 31, 2018
• Study Completion (Actual): December 31, 2018

Study Registration Dates

• First Submitted: July 15, 2019
• First Submitted That Met QC Criteria: July 15, 2019
• First Posted (Actual): July 17, 2019

Study Record Updates

• Last Update Posted (Actual): July 17, 2019
• Last Update Submitted That Met QC Criteria: July 15, 2019
• Last Verified: July 1, 2019

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Urologic Diseases; Congenital Abnormalities; Genetic Diseases, Inborn; Abnormalities, Multiple; Kidney Diseases, Cystic; Ciliopathies; Kidney Diseases; Polycystic Kidney Diseases; Polycystic Kidney, Autosomal Dominant
• Other Study ID Numbers: STH15983

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No